Text Size

Exploratory Study Using Nanotechnology to Detect Biomarkers of Parkinson's Disease From Exhaled Breath

This study is enrolling participants by invitation only.
Sponsor:
Collaborator:
Technion, Israel Institute of Technology
Information provided by:
Rambam Health Care Campus
ClinicalTrials.gov Identifier:
NCT01246336
First received: November 21, 2010
Last updated: November 22, 2010
Last verified: November 2010
History of Changes
  Purpose

Parkinson's disease is diagnosed clinically, because biomarkers that may help in diagnosis and differential diagnosis are not yet available. Exhaled breath testing may yield a "breath-print" that can be used to distinguish healthy and diseased states.


Condition Intervention
Parkinson's Disease
Parkinsonism
 Other: no intervention

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Exploratory Study to Detect Volatile Biomarkers of Idiopathic Parkinson's Disease and Parkinsonism From Exhaled Breath Using a Nanomedical Artificial Olfactory System.

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Rambam Health Care Campus:

Biospecimen Retention:   Samples Without DNA

Exhaled breath


Estimated Enrollment: 100
Study Start Date: August 2009
Groups/Cohorts Assigned Interventions
Patients with parkinsonism
Patients suffering from Parkinson's disease or parkinsonism
Healthy controls
Patients not suffering from Parkinson's disease or any other neurological disorder
 Other: no intervention
no intervention

  Eligibility

Ages Eligible for Study:   30 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Patients diagnosed with Idiopathic Parkinson's disease and Parkinsonism will be included.

Criteria

Inclusion Criteria:

  • Patients with Parkinsonism

Exclusion Criteria:

  • Severe dementia
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01246336

Sponsors and Collaborators
Rambam Health Care Campus
Technion, Israel Institute of Technology
Investigators
Principal Investigator: Ilana Schlesinger, MD Rambam Health Care Campus
  More Information

No publications provided

Responsible Party: Ilana Schleainger, Rambam Health Care Campus
ClinicalTrials.gov Identifier: NCT01246336     History of Changes
Other Study ID Numbers: RMB09-0196
Study First Received: November 21, 2010
Last Updated: November 22, 2010
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Rambam Health Care Campus:
Parkinson's disease, Parkinsonism
Biomarkers
Exhaled breath
Nanothechnology

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
 Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases

ClinicalTrials.gov processed this record on May 16, 2013